Asset Details
Do you wish to reserve the book?
Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial
Do you wish to request the book?
Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial
2015
Overview
Backgrounds
Durability of androgen-deprivation therapy (ADT) for prostate cancer (PC) is limited. Additional selective estrogen receptor modulators (SERMs) may prolong the durability of ADT, because androgen and estrogen signaling drive PC progression.
Methods
Men with treatment-naïve bone metastatic PC were randomly assigned in 1:1:1 fashion to receive ADT, toremifene 60 mg plus ADT (TOPADT), or raloxifene 60 mg plus ADT (RAPADT). The primary endpoint was the biochemical recurrence (BCR) rate, and secondary endpoints were changes of scores of the visual analogue scale (VAS) and the functional assessment of cancer therapy (FACT).
Results
A total of 15 men, 5 each, were allocated to one of the three treatment arms. The basal serum prostate-specific antigen (PSA) level was 198 ng/mL (median, range; 30–8428). Bone metastases were graded as 1 (
n
= 11), 2 (
n
= 3), and 3 (
n
= 1) by the extent of disease. During the median follow-up period of 1370 days (range; 431–1983), BCR occurred in 3, 0 and 2 men in ADT, TOPADT and RAPADT group, respectively. The 5-year BCR-free rate was 30, 100 and 53 %, in ADT, TOPADT and RAPADT group, respectively (
p
= 0.04, ADT v.s. TOPADT,
p
= 0.48, ADT v.s. RAPADT and
p
= 0.12, TOPADT v.s. RAPADT). Scores of VAS improved in all groups and remained stable throughout the study. This analysis is limited as a preliminary result in a single center.
Conclusions
Toremifene with conventional ADT significantly improved the BCR rate in treatment-naïve bone metastatic PC. Further clinical trials are warranted to confirm the promising clinical efficacy of this combination therapy.
Trial registration
The protocol was registered at the University Hospital Medical Information Network (
UMIN ID;0,000,064,000
) in Sep 25, 2011.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V
Subject
/ Androgen Antagonists - administration & dosage
/ Biomedical and Life Sciences
/ Bone Neoplasms - drug therapy
/ Complications and side effects
/ Estrogen Receptor alpha - antagonists & inhibitors
/ Health Promotion and Disease Prevention
/ Humans
/ Male
/ Medical and radiation oncology
/ Neoplasm Recurrence, Local - drug therapy
/ Neoplasm Recurrence, Local - pathology
/ Oncology
/ Patients
/ Prostate-Specific Antigen - blood
/ Prostatic Neoplasms - drug therapy
